Previous 10 | Next 10 |
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear...
Arrowhead Pharmaceuticals, Inc. ( ARWR ) is currently a tremendous value at an over 40% discount to recent highs. A recent upgrade by independent analyst BioBoyScout gives a perfectly reasonable pie-in-the-sky valuation of $107 for Arrowhead based primarily on its expanding partnership with ...
Ligand reports planned acquisition of Pfenex Ligand Pharmaceuticals Inc. ( LGND ) announced that it has inked a definitive agreement with Pfenex Inc. ( PFNX ) for acquiring the latter. The companies expect the transaction to be closed in the fourth quarter of 2020, subject to required re...
Dosing is underway in a Phase 1/2 clinical trial evaluating Arrowhead Pharmaceuticals' (NASDAQ: ARWR ) ARO-ENaC, an RNAi therapeutic, in cystic fibrosis (CF) patients. More news on: Arrowhead Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis ...
Investment Thesis Arrowhead Pharmaceuticals, Inc. ( ARWR ) is an established active investment alternative in competition with dozens of other more recent biotech developer research enterprises. Success from an investment point of view relates more to increased stock price than lives saved...
Image source: The Motley Fool. Arrowhead Pharmaceuticals, Inc (NASDAQ: ARWR) Q3 2020 Earnings Call Aug 5, 2020 , 4:30 p.m. ET Operator Continue reading
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations Christopher Anzalone - President & Chief Executive Officer Javier San Martin - Chief Medical Officer...
Arrowhead Pharmaceuticals ( ARWR -1.2% ) fiscal Q3 results : More news on: Arrowhead Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) : Q3 GAAP EPS of -$0.13 beats by $0.04 . More news on: Arrowhead Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14, 2024, 9:30 a.m. EDT...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiM TM ) platform. Eac...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may acc...